Location: Multi-centers in the US

Purpose: The primary objective of the study is to assess the clinical efficacy of Rebif 44 mcg three times per week compared with Copaxone 20 mg daily in patients with relapsing MS.

Eligibility:
• Males and females between 18 and 60 years of age
• Diagnosis of RRMS
• Have had one or more relapses within the prior 12 months
• Must be in a clinically stable or improving neurological state during the 4 weeks prior to study day 1.
There are also several exclusion criteria.

Procedure: This randomized study is an open-label study where Rebif 44 mcg administered three times per week by subcutaneous injection is compared with Copaxone 20 mg administered daily by subcutaneous injection in the treatment of RRMS.

Benefit: This Phase IV study may lead to an improved treatment for MS.

For Information: Contact the NARCOMS office at 1-800-253-7884.

This entry was posted on Monday, July 11th, 2005 at 9:45 pm and is filed under All Articles, MS Study Enrollments. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.